Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (181-190 of 251) with videos related to

Pageof 26
Sort By:
Blood|May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalitiesAurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Bone Marrow Transplantation|November 4, 2023
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndromeSamia Harbi, Louison Brac de la Perriere, Benjamin Bouchacourt, et al.
Oncogene|November 16, 2004
Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profilingNorbert Vey, Marie-Joëlle Mozziconacci, Agnès Groulet-Martinec, et al.
Cancer|March 19, 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignanciesGautam Borthakur, Leslie Popplewell, Michael Boyiadzis, et al.
European Journal of Haematology|January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemiaXavier Cahu, Martin Carré, Christian Recher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First RemissionXavier Thomas, Stéphane de Botton, Sylvie Chevret, et al.
Leukemia Research|March 15, 2011
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 casesThorsten Braun, Stéphane de Botton, Anne-Laure Taksin, et al.
Haematologica|August 27, 2013
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupSarah Bertoli, Pierre Bories, Marie C Béné, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Pageof 26

Showing results (181-190 of 251) with videos related to

Sort By:
Pageof 26
Blood|May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalitiesAurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Bone Marrow Transplantation|November 4, 2023
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndromeSamia Harbi, Louison Brac de la Perriere, Benjamin Bouchacourt, et al.
Oncogene|November 16, 2004
Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profilingNorbert Vey, Marie-Joëlle Mozziconacci, Agnès Groulet-Martinec, et al.
Cancer|March 19, 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignanciesGautam Borthakur, Leslie Popplewell, Michael Boyiadzis, et al.
European Journal of Haematology|January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemiaXavier Cahu, Martin Carré, Christian Recher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First RemissionXavier Thomas, Stéphane de Botton, Sylvie Chevret, et al.
Leukemia Research|March 15, 2011
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 casesThorsten Braun, Stéphane de Botton, Anne-Laure Taksin, et al.
Haematologica|August 27, 2013
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupSarah Bertoli, Pierre Bories, Marie C Béné, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Pageof 26